Open AccessFrankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways
Author(s) -
Piao Zheng,
Zhen Huang,
Dong-chang Tong,
Qing Zhou,
Sha Tian,
Bo-Wei Chen,
Di-Min Ning,
Yinmei Guo,
Wenhao Zhu,
Yan Long,
Wei Xiao,
Zhe Deng,
Yi-Chen Lei,
Xuefei Tian
Publication year - 2022
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v14.i2.450
Subject(s) - medicine , hepatocellular carcinoma , pharmacology , in vivo , apoptosis , signal transduction , h&e stain , cancer research , cd31 , angiogenesis , pathology , traditional medicine , biology , staining , microbiology and biotechnology , biochemistry
In traditional Chinese medicine (TCM), frankincense and myrrh are the main components of the antitumor drug Xihuang Pill. These compounds show anticancer activity in other biological systems. However, whether frankincense and/or myrrh can inhibit the occurrence of hepatocellular carcinoma (HCC) is unknown, and the potential molecular mechanism(s) has not yet been determined.